Human CD4+ or CD8+ TCR-KO NFAT Reporter Jurkat T Cell Lines

Background

T cells are central mediators of adaptive immunity and play a critical role in the recognition and elimination of infected or malignant cells. Their activity is driven by highly specialized T cell antigen receptors (TCRs), which recognize short antigenic peptides presented by major histocompatibility complex (MHC) molecules at the surface of antigen-presenting cells (APCs). CD8⁺ cytotoxic T cells recognize peptide-MHC class I complexes and mediate the elimination of virus-infected or tumor cells, whereas CD4⁺ T helper (Th) cells recognize peptide-MHC class II complexes and coordinate broader immune responses through cytokine secretion and immune cell activation [1,2].

The “classical” and most abundant TCR is an 80 - 90 kDa heterodimer composed of one α chain and one β chain. This αβTCR is a transmembrane receptor expressed by developing and mature T cells and contains an extracellular ligand-binding domain together with a short cytoplasmic tail. Each αβTCR specifically recognizes a defined peptide-MHC complex. However, due to its limited intracellular domain, the TCR cannot signal independently and therefore relies on non-covalent association with the CD3 signaling complex to initiate downstream signaling events leading to T cell activation [3,4]. Co-receptors such as CD4 and CD8 further stabilize peptide-MHC recognition and amplify TCR-mediated signaling [1,2].

Upon TCR engagement, intracellular signaling cascades induce calcium influx, leading to activation of the nuclear factor of activated T cells (NFAT) pathway. Calcium-bound calmodulin activates the phosphatase calcineurin, which dephosphorylates NFAT proteins and promotes their translocation into the nucleus. Nuclear NFAT then regulates the expression of numerous genes involved in T cell activation, proliferation, cytokine production, and effector functions [5,6]. Co-stimulatory signaling through CD28 additionally enhances NFAT activation via the AKT signaling pathway [6].

The highly specific recognition of peptide-MHC complexes by TCRs has made TCR-engineered T cell therapy (TCR-T) a promising strategy in cancer immunotherapy and adoptive cell therapy. However, functional characterization of candidate TCRs remains technically challenging due to donor variability, heterogeneous activation states, and the potential mispairing between endogenous and introduced transgenic TCR α/β chains [2]. To address these limitations, engineered reporter T cell systems such as Jurkat-based NFAT reporter cell lines have emerged as robust and standardized platforms for the reproducible evaluation of TCR specificity, avidity, signaling, and function [1,2].

References:

1. Müller TR, et al., 2020. A T-cell reporter platform for high-throughput and reliable investigation of TCR function and biology. Clin Transl Immunology. 9(11):e1216.
2. Grailer J, et al., 2023. A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. J Immunother. 46(3):96-106. 
3. Budd R.C. & Fortner K.A., 2017. Chapter 12 - T Lymphocytes. Kelley and Firestein's Textbook of Rheumatology (Tenth Edition). pages 189-206.
4. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.
5. Lee J-U., et al., 2018. Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases. Front Immunol. DOI: 10.3389/fimmu.2018.02747.
6. Macian F., 2005. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 5(6):472-484.